Dr. Jamie Hook, MD, and her team, Aerosome Therapeutics, are using Aerosome-01 to target ARDS, a large, underserved market with over 200,000 U.S. cases annually, 30-45% mortality, and no FDA-approved disease-modifying therapies. Aerosome-01 is an inhaled mRNA lipid nanoparticle (LNP) therapeutic designed to deliver a regenerative protein directly to damaged alveolar epithelial cells, accelerating epithelial barrier repair and restoring lung function in patients with ARDS. Aerosome-01’s inhaled mRNA-LNP platform directly repairs the injured alveolar epithelium, addressing a major unmet clinical need while creating a multibillion-dollar commercial opportunity.
This first-in-class targeted therapy directly repairs the alveolar epithelial barrier with localized lung delivery, limited systemic exposure, and a non-immunosuppressive mechanism, having the potential to reduce mortality, ICU stay, and long-term complications of ARDS.
ConduITS is supported by NCATS of the NIH’s CTSA Program. Any use of CTSA-supported resources requires citation of grant number UL1TR004419 awarded to ISMMS in the acknowledgment section of every publication resulting from this support. Adherence to the NIH Public Access Policy is also required.
